Phase 2 PROTECT Trial Evaluates ProTmune for Prevention of Acute Graft-Versus-Host Disease

News

Fate Therapeutics has initiated enrollment in the Phase 2 stage of PROTECT, a combined, open-label Phase 1/2 clinical trial evaluating ProTmune for the prevention of acute graft-versus-host disease (GvHD) in ... Read more

April 21, 2017

Manipulating Select T-cells May Prevent Dangerous Side Effect of Stem Cell Therapy

News

Controlling the balance of two subsets of immune T-cells, known as CD4+ and CD8+, after stem cell transplants makes it possible to prevent graft-versus-host disease (GVHD) while keeping the anti-cancer ... Read more